The American Society for Aesthetic Plastic Surgery (ASAPS), is hosting a panel discussion about the latest best practices and uses for injectables including the newest FDA-approved options at The Aesthetic Meeting today in Montreal, Quebec Canada.
The panel discussed the latest advances, including the ways various dermal fillers can be utilized to produce optimal results for targeted areas. There are thirteen FDA-approved dermal fillers on the market to-date, providing aesthetic plastic surgeons with the ability to customize anti-aging treatments to patients’ needs. “The filler choices are dictated by a patient’s unique aging pattern, the anatomical area to be treated and physiochemical properties,” explains ASAPS member, Dr. Z. Paul Lorenc.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310753-asaps-facial-rejuvenation-injectables/
Having trouble selling your music using Facebook ads? Apply this simple 2-minute targeting trick and you're virtually guaranteed to get better results.
https://www.youtube.com/watch?v=D5c92rjQqzA
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Bilimi, gerçekleri anlatmak suç değildir. Biyolojinin temeli olan evrim, hak ettiği şekilde müfredetta yer almalıdır. Bugün bunu yapanlara yarın, dünya düz diyenlere gülündüğü gibi gülünecektir.
#EvrimiSavunuyorum
https://www.youtube.com/results?q=%23EvrimiSavunuyorum
Results from a large retrospective data analysis published in the American Journal of Transplantation (AJT) today, showed that liver transplantation patients who were treated early with Advagraf experienced a significantly increased graft survival benefit of 8% at 3 years post-transplant compared with patients treated with the current standard of care, tacrolimus immediate release (twice daily).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7451251-advagraf-prolonged-release-tacrolimus/
In its annual report on the EU budget published today, the European Court of Auditors (ECA) warns that the budget system is too focused on just getting funds spent and needs to place more emphasis on achieving results. As independent auditor, the ECA signed off the 2013 accounts of the European Union, but stresses that the management of EU spending is not yet good enough overall - either at EU level or in the Member States.
Throughout the 2007 to 2013 spending period, say the EU Auditors, the priority was given to spending the money - ‘use it or lose it’ - rather than to achieving good results. For instance, the choice of projects to receive EU funds focused first on disbursing the EU money available, secondly on complying with the rules, and only then - and to a limited extent - on results and impact.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762585-EU-must-focus-on-better-results/
Graph plotter program plots 2D graphs from complex equations. The application comprises algebraic, trigonometric, hyperbolic and transcendental functions. EqPlot can be used to verify the results of nonlinear regression analysis program.
Equation graph plotter gives engineers and researchers the power to graphically review equations, by putting a large number of equations at their fingertips. The program is also indispensable for students and teachers.
MarketingSherpa’s tenth annual MarketingSherpthe only email marketing conference based on proven research and science, will be held February 19-22 at the Paris Las Vegas Hotel & Casino.
Four power-packed days of hands-on training includes 25 speakers, 30 roundtable discussions and eight breakout sessions. Five tactical trainings will focus on optimizing email marketing programs, and leveraging analytics and testing to gauge results and return on investment.
To view Multimedia News Release, go to http://www.multivu.com/players/English/59419-meclabs-email-summit-2013/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and haemodynamic monitoring, announced the results of a pivotal clinical study of high-risk surgical patients with severe aortic stenosis treated in Cohort A of The PARTNER Trial. These data demonstrate that the study achieved its primary endpoint at one year, concluding that survival of patients treated with the Edwards SAPIEN transcatheter aortic valve was equivalent to those treated with surgical aortic valve replacement. The data were presented at the American College of Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New Orleans, LA, USA.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/48895/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
As another school year ends, American parents once again face the challenge of making sure their kids get enough daily physical activity to keep them occupied throughout the summer. Based on the results of a recent national survey of parents with children ages 3-17, that may be easier said than done.
While the U.S. Centers for Disease Control and Prevention recommends that kids have at least 60 minutes of daily physical activity, the Let’s Play 2016 State of Play Survey, commissioned by Dr Pepper Snapple Group (NYSE: DPS), revealed that only one out of three children participates in daily active play.
There also appears to be a significant drop in daily active play when most children head off to kindergarten. Half of 4-year-olds get active daily playtime, compared to 31 percent of 5-year-olds.
To view the multimedia release go to:
http://www.multivu.com/players/English/7816051-dr-pepper-snapple-lets-play/
